Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research
29 juil. 2021 10h00 HE
|
Celsion CORP
Data show dose-dependent suppression of immune-suppressive agents GEN-1 stimulates the immune system through the production of CD4 and CD8 cells Chemotherapy Response...
Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®
23 juin 2021 08h00 HE
|
Celsion CORP
Celsion GmbH will manage current and future cancer studies with ThermoDox® Celsion continues its strategic focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J., June 23, 2021 ...
Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses
11 mai 2021 08h00 HE
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J., May 11, 2021 ...
Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study
08 sept. 2020 08h35 HE
|
Celsion CORP
Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company,...
Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020
07 août 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second...
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
14 juil. 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its...
Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020
08 mai 2020 09h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the first...
Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm
26 mars 2020 08h00 HE
|
Celsion CORP
Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage...
Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
17 déc. 2019 08h00 HE
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming...
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
14 nov. 2019 16h05 HE
|
Celsion CORP
Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB)...